Discovery Life Sciences Acquires AllCells

Discovery Life Sciences (Discovery), a company specializing in biomarkers and biospecimens, announced its acquisition of AllCells, a provider of human primary blood and marrow-based cells. Discovery plans to combine its existing cell and gene therapy products and services with AllCells to create a business unit called AllCells, a Discovery Life Sciences company. AllCells CEO and President Danny Zheng will lead the entity.

“We are very excited to welcome the AllCells team to the Discovery family,” said Glenn Bilawsky, CEO, Discovery Life Sciences, in a July 12, 2022 company press release. “Bringing these two great companies together creates a scalable, end-to-end solution that gives our clients unprecedented access to reliable human cellular starting materials with integrated multi-omic analytic services to support cell and gene therapies.”

According to the press release, the acquisition grants Discovery access not only to their cell supplies, but also starting materials and analytic services to accelerate cell and gene therapy experiences. Additionally, Discovery’s newly acquired FDA-registered donor collection facilities and good manufacturing practice (GMP)-compliant cleanrooms are adjacent to characterization labs; this placement enables immediate processing and cryopreservation.

“We have built our organization to be an extension of our client's supply chain. By offering donor program consulting, high-quality apheresis collections, customization services, and GMP-compliant starting materials, our dedicated team will continue to provide a high-touch, client-focused approach to ensure our clients' needs are met with superior products and services to fit any timeline and on any scale,” said Zheng in the press release. “Our strategy parallels and reinforces Discovery's 'Science at your Service' approach, and our unified offerings will further accelerate our clients' strategic and vital cell and gene therapy programs.”

Source: Discovery Life Sciences